-1366x0.jpg)
On March 22-23, 2025, Clinical Embryology Conference 2025 - organized by the Ho Chi Minh City Association of Reproductive Endocrinology and Infertility (HOSREM) will be held at Wyndham Legend Halong Hotel, No. 12 Bai Chay, Ha Long City, Quang Ninh. GENTIS Genetic Testing Service Joint Stock Company is honored to be a sponsor of the conference.
The 6th CEC is a specialized conference on clinical embryology and new technical and technological applications in assisted reproduction. This year's conference will update knowledge, technical trends, technology, and new protocols in assisted reproductive techniques.
At the exhibition booth at the conference, GENTIS will focus on introducing solutions in genetic screening and diagnosis in the field of assisted reproduction, especially 2 new PGT test packages: PGT NEXT and PGT UPGRADE
PGT UPGRADE
PGT UPGRADE is a pre-implantation genetic analysis test that can detect aneuploidy on 24 chromosomes, additional abnormalities, chromosomal deletions with a size of over 5 Mb, especially capable of detecting embryos carrying balanced translocations inherited from the parents. Chromosomal translocations are structural abnormalities of chromosomes caused by the rearrangement of large segments between non-homologous chromosomes. There are two types of translocations: balanced (no loss of genetic material) and unbalanced (loss or extra genetic material, such as aneuploidy). When both the father and mother carry balanced translocations, approximately 60% of gametes will carry unbalanced translocations, leading to embryos with chromosomal abnormalities. This is also a common cause of repeated implantation failure, recurrent miscarriage, and birth defects. PGT UPGRADE test helps to select euploid embryos for parents carrying balanced translocations to increase the chance of having a healthy baby. In addition, PGT UPGRADE also supports providing genetic information for the embryo selection process before embryo transfer.
Performing PGTest testing can select genetically good quality embryos to increase the chance of pregnancy when performing in vitro fertilization (IVF), helping to increase the chance of the child being born healthy, without the screened genetic abnormalities.
Detection range:
- Aneuploidy of all 24 chromosomes.
- Chromosome structural abnormalities (addition, deletion) with a size of over 5 Mb.
- Detecting embryos carrying balanced genetic translocations from parents.
Method: Next-generation sequencing NGS (Illumina) and analyzing sequencing results using specialized bioinformatics software.
Samples used:
- Parental samples (2-3 ml whole blood in EDTA anticoagulant tube) and balanced translocation test results.
- Embryo biopsy sample on day 5.
Time to return results: 12 – 14 days.
PGT NEXT
PGT NEXT is a pre-implantation genetic analysis test that can detect aneuploidy on 24 chromosomes, chromosomal abnormalities, and chromosomal deletions. It can also detect embryos with polyploidy or haploidy. This helps avoid transferring polyploid/haploidy abnormal embryos, and avoid wasting euploid embryos with fertilization abnormalities (0PN, 1PN, and 2.1/3PN). In addition, the PGT UPGRADE test also supports the provision of genetic information for embryo selection before embryo transfer. The combination of NGS whole genome sequencing with SNP analysis improves the resolution of genetic screening for polyploidy.This method allows for the identification of haploid and polyploid chromosome sets, increasing the number of healthy euploid embryos available for transfer by accurately detecting true diploid embryos among abnormally fertilized embryos (0PN, 1PN, 2.1PN, 3PN). Additionally, SNP analysis ensures precise identification of whether the tested embryo is genetically related to other embryos in the same cohort, thereby reducing the risk of sample mix-ups due to procedural or handling errors.
Detection range:
- Aneuploidy of all 24 chromosomes.
- Chromosomal structural abnormalities (addition, deletion).
- Detection of embryos with polyploidy or haploidy.
Method: Whole genome sequencing and sequencing of target markers on the next generation sequencing machine NGS.
Samples used: Embryo biopsy sample on day 5.
Time to return results: 3 – 4 weeks.
Not only that, GENTIS's booth also provides the latest genetic testing documents in the field of assisted reproduction and prepares many attractive gifts of gratitude to the delegates
️We respectfully invite doctors/ embryologists/ experts to visit GENTIS's booth to update the most modern and advanced pre-implantation genetic screening testing solutions, serving the needs of better medical examination and treatment of Vietnamese people.
